PhotoCure ASA (FRA:PHS) Moat Score: 4/10 (As of Jun. 26, 2026)


FRA:PHS PhotoCure ASA FRA:PHS
73 GF Score
Price €5.23
GF Value €6.33
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA Moat Score?

PhotoCure ASA FRA:PHS -1.32% 73 Moat Score is 4 as of Jun. 26, 2026. GuruFocus rates FRA:PHS with a GF Score™ of 73/100 and a GF Value™ of €6.33 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,033 Drug Manufacturers companies, PhotoCure ASA ranks better than 90.71% on this metric.

PhotoCure ASA has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

PhotoCure ASA has Narrow Moat: PhotoCure ASA has valuable intellectual property and patents in the medical field, providing some competitive edge. However, it lacks strong brand strength and significant regulatory barriers, resulting in a modest moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PhotoCure ASA might have Narrow Moat - Discernible but modest moat.

PhotoCure ASA  (FRA:PHS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PhotoCure ASA Moat Score Related Terms

FRA:PHS vs ZTS, UTHR, VTRS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhotoCure ASA Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Moat Score distribution charts can be found below:

* The bar in red indicates where PhotoCure ASA's Moat Score falls into.


FRA:PHS
73GF Score
PhotoCure ASA FRA:PHS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
PhotoCure ASA (FRA:PHS) has a Moat Score of 4 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PhotoCure ASA ranks #96 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is PhotoCure ASA's Moat Score too high?
PhotoCure ASA's current Moat Score is 4. Based on the distribution chart, PhotoCure ASA ranks #96 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PhotoCure ASA has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #96 out of 1033 companies for Moat Score. This places PhotoCure ASA in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. PhotoCure ASA's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.33, compared to a current price of €5.23 — trading 17.4% below its estimated fair value. The current Moat Score is 4. PhotoCure ASA's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Moat Score is 4 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of €5.23 is trading 17.4% below its estimated GF Value™ of €6.33. GuruFocus considers PhotoCure ASA to be Modestly Undervalued.

Key valuation signals for FRA:PHS:

  • Moat Score: 4
  • GF Value™: €6.33 vs. price of €5.23 (17.4% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
73GF Score

Get the complete analysis for FRA:PHS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.23
Price
€6.33
GF Value